Global Microneedle Drug Delivery Systems Market Size, Forecast, and Trend Highlights Over 2025-2037
Microneedle Drug Delivery Systems Market size was valued at USD 812.47 million in 2024 and is expected to cross USD 2.08 billion by the end of 2037, registering more than 7.5% CAGR during the forecast period i.e., between 2025-2037. In 2025, the industry size of microneedle drug delivery systems is evaluated at USD 855.12 million.
The market is estimated to grow on the back of the increasing prevalence of chronic conditions such as diabetes, cancer, heart disease, and stroke. According to the International Diabetes Federation, around 589.0 million adults aged between 20 and 79 were affected by diabetes worldwide, which is projected to reach 853.0 million by 2050. Another NLM prediction revealed that the annual count of new and death cases of cancer is poised to be 26.0 million and 17.0 million by 2030, respectively. On the other hand, several studies have shown improved results from using this type of therapy in managing these diseases. In addition, the wide use of microneedling in dermatology, such as removing acne scars, is also fueling growth in this sector.
As per NLM, the net global cost of chronic ailments has the potential to attain USD 47.0 trillion by 2030. Thus, the magnifying economic burden on patients with such illnesses is pushing the market to curate more accessible solutions with lower payers’ pricing. In selective cases, its therapeutic approach has also been proven to be a value-based solution. On this note, a publication from the Indian Association of Dermatologists, released in February 2025, established microneedling as a more cost-effective alternative to autologous platelet-rich plasma (PRP) treatment for acne scars. The study testified this fact with the associated benefits, including fewer side effects and quicker recovery, where PRP resulted in post-inflammatory hyperpigmentation among 10.0% of candidates.
Microneedle Drug Delivery Systems Sector: Growth Drivers and Challenges
Growth Drivers
- Advancements in drug delivery systems: As the utility of products from the microneedle drug delivery systems market rises in various medical disciplines, the surge for more innovative options is increasing. This is influencing companies to incorporate new materials and smart technologies, such as biodegradable regimens, in their pipeline. On the other hand, these commodities are gaining traction for delivering efficiency and safety while maintaining compliance with regulatory standards. Thus, continuous upgrades in products are an indication of greater global penetration and higher revenue generation.
- Extended application in biologics delivery: Currently, the technology used in the market is also being utilized for large-scale vaccination. Vaccine reluctance due to fear of needles, pain, and side effects is becoming a serious problem for global health authorities, particularly during pandemics. According to a survey published by NLM, the acceptance rate of COVID-19 vaccines in the U.S. was only 56.9% till April 2020, and the same was 40.0% in Hong Kong till March. This issue can be mitigated by this needle-free vaccine delivery due to its minimally invasive nature, inflating demand in this sector.
Challenges
- Concerns associated with the system: Drug degradation, poor absorption, and local discomfort are some of the major concerns associated with the products from the market. Both coated and hollow microneedles possess the risk that the drug may not properly enter the skin and may not be effective. Some of the material used to construct these systems cannot be absorbed by the body, and any fragments of them may create irritation, resulting in consumer dissatisfaction and limitation in wide adoption.
Microneedle Drug Delivery Systems Market: Key Insights
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
7.5% |
|
Base Year Market Size (2024) |
USD 812.47 million |
|
Forecast Year Market Size (2037) |
USD 2.08 billion |
|
Regional Scope |
|
Microneedle Drug Delivery Systems Segmentation
Material (Silicon, Metal, Polymer)
The metal segment is anticipated to garner the largest revenue share of 44% in the microneedle drug delivery systems market over the assessed timeline. The leadership of this segment is attributable to the rising number of cosmetic procedures performed with metal microneedles array to treat acne, stretch marks, hair loss, and more. In addition, this subtype is also widely used for treating various malignancies. For instance, an NLM study from December 2022 mentioned several examples of the utility of metallic microneedles (MNs). One of them was 1100 μm long and was used in treating breast cancer, demonstrating 5 times higher tumor suppression. Similarly, it mentioned the utilization of metallic MN arrays in ovarian and skin cancer, showcasing tumor suppression within 5 minutes and 90.0% drug delivery efficacy.
Type (Solid, Hollow, Dissolving, Coated)
In terms of type, the hollow segment is poised to gain notable traction in the microneedle drug delivery systems market by 2037. The most important driving factor in this segment is the high compliance with patients, clinicians, healthcare administrators, and regulators, owing to its long-acting and safe characteristics. Ongoing R&D initiatives and rising demand for alternatives with better safety profiles in comparison to traditional hypodermic injections are making this type of MN more desirable. In addition, the introduction of 3D printing is mitigating the limitations in the fabrication of these solutions, solidifying their leadership in large-dose administration and molecular-weight substances.
Our in-depth analysis of the global microneedle drug delivery systems market includes the following segments:
|
Type |
|
|
Material |
|
|
Application |
|
|
End user |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportMicroneedle Drug Delivery Systems Industry - Regional Synopsis
North American Market Forecast
The North America microneedle drug delivery systems market is anticipated to garner the largest share of 36% throughout the discussed timeframe. The rise in this region is attributable to the wide adoption of highly advanced processes and systems in MN production. The significant growth is also a result of the increased knowledge among the citizens about the existence of such revolutionary medication methods. This can be testified by the projected dominant captivity of North America in the global dermabrasion and microneedling industry, with a share of 40.6% by 2037. Furthermore, the enlarging population with chronic diseases is fostering a wider consumer base for this sector.
The estimated number of habitats in the U.S. with at least 1 chronic illness was 129.0 million in 2024: CDC. This demography signifies the presence of a promising business flow in this country. In addition, the popularity of minimally invasive cosmetic transformations is growing, where the count of similar surgical procedures in this country was 13,281,235 in 2020: American Society of Plastic Surgeons (ASPS). This showcases an accepting culture towards the market, attracting domestic pharma giants to participate. On this note, in May 2020, 3M relaunched its subsidiary business of drug delivery systems under a new brand name, Kindeva Drug Delivery, to possess microneedling technology. This transition was backed by the USD 650.0 million worth of Kindeva acquisition.
APAC Market Forecast
Asia Pacific is expected to expand quickly in the microneedle drug delivery systems market, owing to factors such as population growth, changing lifestyles, increased patient awareness, and rising per capita spending. Additionally, developing nations such as China and India are strengthening their healthcare systems, which are backed by economic development and enlargement in the cosmetic industry. Furthermore, the strong emphasis of these nations on manufacturing medical instruments and biotechnology is escalating their global significance in this field. For instance, in 2020, the biotechnology industry in India surpassed USD 70.2 billion; it is further poised to gain USD 150.0 billion by 2025 and up to USD 300.0 billion by 2030 (IBEF).
China, with a large patient population and an emerging medical device industry, is augmenting the regional market. According to WHO statistics, stroke was the top cause of death in this country in 2021, with a rate of 117.8 per 100,000. It also highlighted the worsening mental health condition in China with increasing suicidal mortality. Thus, the country demands large-scale medicine administration, particularly during pandemics, creating scope for advanced delivery systems such as MNs. In addition, the medical device merchandise in this nation is expected to reach USD 48.8 billion by 2026, where diagnostic imaging and consumables acquire 50.0%. The complete scenario represents a lucrative trading opportunity for global pioneers.
Companies Dominating the Microneedle Drug Delivery Systems Landscape
- ICU Medical Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Becton, Dickinson, and Company
- B. Braun Medical Inc.
- NanoPass Technologies Ltd
- Thermo Fisher Scientific
- Cardinal Health, Inc.
- 3M
- TheraJect, Inc.
- Siemens Healthcare GmbH
- Raphas Co., Ltd.
- Daewoong Pharmaceutical
- Revive Therapeutics Ltd.
The dermatology category is becoming a prime focus for key players in the market. They are continuously evolving the method and components of their offerings to make treatment more effective and durable. For instance, in February 2023, Candela introduced a multi-application system, Profound Matrix, featuring the Sublime, Sublative RF, and Matrix Pro applicators. This FDA-approved microneedling device is designed to deliver bipolar radiofrequency treatments and to regenerate & build new collagen to correct, maintain, and restore skin at various stages of aging. Furthermore, several MedTech pioneers are also conducting rigorous studies to establish new applications of their pipelines. Such key players are:
In the News
- In October 2024, Daewoong Pharmaceutical displayed its cutting-edge drug delivery technologies, including the microneedle-based drug pipeline, at CPHI Worldwide 2024. It also shared its recently developed microneedle platform, CLOPAM, offering enhanced drug uniformity and stability through aerodynamic crafting and hermetic packaging.
- In February 2023, Revive Therapeutics collaborated with PharmaTher Holdings to develop a 3,4-Methylenedioxy​methamphetamine (MDMA) transdermal patch. The evaluation was based on proving the efficacy of PharmaTher’s novel microneedle patch in delivering this medicine for treating depression, anxiety, and other mental disorders.
Author Credits: Radhika Pawar
- Report ID: 4258
- Published Date: Apr 28, 2025
- Report Format: PDF, PPT
